Figure 1
Figure 1. PK/PD studies. (A) ALX-0081 plasma concentrations. (B) VWF-RiCof activity. (C) Ristocetin-induced vWF binding to platelets as assessed by flow cytometry. ALX-0081 doses: (●) 1.25 mg/kg; (□) 2.5 mg/kg; (shaded triangle) 5 mg/kg; (▪) vehicle. (D) Platelet adhesion on a collagen-coated surface under high shear stress (3000 sec−1) expressed as percentage of the surface covered by platelets. *P < .05 vs vehicle and tirofiban; n = 5 per group.

PK/PD studies. (A) ALX-0081 plasma concentrations. (B) VWF-RiCof activity. (C) Ristocetin-induced vWF binding to platelets as assessed by flow cytometry. ALX-0081 doses: (●) 1.25 mg/kg; (□) 2.5 mg/kg; (shaded triangle) 5 mg/kg; (▪) vehicle. (D) Platelet adhesion on a collagen-coated surface under high shear stress (3000 sec−1) expressed as percentage of the surface covered by platelets. *P < .05 vs vehicle and tirofiban; n = 5 per group.

Close Modal

or Create an Account

Close Modal
Close Modal